Click to toggle navigation menu.
FAQ: FDA Modification of the Mifepristone REMS

On December 16, 2021, the U.S. Food and Drug Administration (FDA) announced modifications to the mifepristone REMS were warranted to reduce burden on patient access and the healthcare delivery system and to ensure the benefits of the product outweigh the risks.

Click below for answers to frequently asked questions on this update.

Message Guidance on the FDA’s REMS on Medication Abortion Care (Jan 2023)

Talking Points on State Bans & Restrictions on Medication Abortion Care

Talking About Abortion in a Post-Roe World